Literature DB >> 24659919

PSA Velocity in Risk Stratification of Prostate Cancer.

Marc A Bjurlin1, Stacy Loeb1.   

Abstract

Entities:  

Year:  2013        PMID： 24659919      PMCID： PMC3922327     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  15 in total

1.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

2.  Prostate cancer: why is PSA velocity such a sticky concept?

Authors:  Andrew J Vickers
Journal:  Nat Rev Urol       Date:  2013-03-12       Impact factor: 14.432

3.  Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility.

Authors:  Andrew J Vickers; Michael J Pencina
Journal:  Eur Urol       Date:  2013-03-13       Impact factor: 20.096

4.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Authors:  Andrew J Vickers; Cathee Till; Catherine M Tangen; Hans Lilja; Ian M Thompson
Journal:  J Natl Cancer Inst       Date:  2011-02-24       Impact factor: 13.506

5.  Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

Authors:  Stacy Loeb; E Jeffrey Metter; Donghui Kan; Kimberly A Roehl; William J Catalona
Journal:  BJU Int       Date:  2012-02-01       Impact factor: 5.588

6.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Authors:  H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

7.  Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Authors:  David Ulmert; Angel M Serio; Matthew F O'Brien; Charlotte Becker; James A Eastham; Peter T Scardino; Thomas Björk; Göran Berglund; Andrew J Vickers; Hans Lilja
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

8.  Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.

Authors:  Scott E Eggener; Ofer Yossepowitch; Kimberly A Roehl; Stacy Loeb; Xiaoying Yu; William J Catalona
Journal:  Urology       Date:  2008-03-21       Impact factor: 2.649

9.  Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

Authors:  Tineke Wolters; Monique J Roobol; Chris H Bangma; Fritz H Schröder
Journal:  Eur Urol       Date:  2008-03-11       Impact factor: 20.096

10.  Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality.

Authors:  David D Ørsted; Stig E Bojesen; Pia R Kamstrup; Børge G Nordestgaard
Journal:  Eur Urol       Date:  2013-02-04       Impact factor: 20.096
View more
  3 in total

Review 1.  The interaction of Wnt-11 and signalling cascades in prostate cancer.

Authors:  Sarah Koushyar; Guy H Grant; Pinar Uysal-Onganer
Journal:  Tumour Biol       Date:  2016-08-11

2.  Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study.

Authors:  Liam King; David Christie; Devinder Arora; Shailendra Anoopkumar-Dukie
Journal:  Prostate Int       Date:  2019-11-30

3.  A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy.

Authors:  Jordan Hart; Briohny Spencer; Catherine M McDermott; Russ Chess-Williams; Donna Sellers; David Christie; Shailendra Anoopkumar-Dukie
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.